{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T04:40:15Z","timestamp":1756269615804,"version":"3.44.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>This case report describes a 59-year-old male with HBV-associated hepatocellular carcinoma who developed progressive atherosclerotic cardiovascular disease (ASCVD) during sequential treatment with sorafenib and regorafenib. Initial sorafenib therapy (400 mg twice daily) led to hand-foot syndrome, necessitating dose reduction, and subsequently resulted in the onset of hypertension (152\/92 mmHg), proteinuria (3+), and microscopic hematuria (2+). Due to disease progression, the patient was transitioned to regorafenib (160 mg daily), during which time he experienced worsening vascular toxicity manifested as lower extremity arterial occlusion, non-ST elevation myocardial infarction, and cerebral ischemia. Angiography revealed critical multivessel coronary disease (95-99% left anterior descending artery [LAD] stenosis) and complete femoropopliteal occlusion, requiring revascularization procedures. Notably, these severe ASCVD manifestations occurred despite a low baseline cardiovascular risk (10-year ASCVD risk of 4.5%) and the absence of traditional risk factors, underscoring the cumulative atherogenic effects of sequential vascular endothelial growth factor (VEGF) pathway inhibition. This case highlights the importance of continuous cardiovascular monitoring during tyrosine kinase inhibitor therapy, particularly when transitioning between agents.<\/jats:p>","DOI":"10.3389\/fonc.2025.1615472","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T04:14:15Z","timestamp":1756268055000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Sorafenib-to-regorafenib sequence-induced atherosclerotic cardiovascular disease: a novel case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Changli","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianghua","family":"Quan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanbo","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haijun","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15174345","article-title":"Potential predictive biomarkers of systemic drug therapy for hepatocellular carcinoma: anticipated usefulness in clinical practice","volume":"15","author":"Motomura","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2024.8","article-title":"Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness","volume":"26","author":"Mongiardi","year":"2024","journal-title":"Expert Rev Mol Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102040","article-title":"CuET overcomes regorafenib resistance by inhibiting epithelial-mesenchymal transition through suppression of the ERK pathway in hepatocellular carcinoma","volume":"47","author":"Ma","year":"2024","journal-title":"Transl Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X15580743","article-title":"Management of regorafenib-related toxicities: a review","volume":"8","author":"Krishnamoorthy","year":"2015","journal-title":"Therap Adv Gastroenterol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2017.1338955","article-title":"Regorafenib for the treatment of unresectable hepatocellular carcinoma","volume":"17","author":"Rimassa","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"B6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12365","article-title":"The adverse effects of sorafenib in patients with advanced cancers","volume":"116","author":"Li","year":"2015","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2896","article-title":"Cardiovascular adverse events in patients with hepatocellular carcinoma receiving vascular endothelial growth factor inhibitors","volume":"44","author":"Yuan","year":"2024","journal-title":"Pharmacotherapy"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100338","article-title":"Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management","volume":"7","author":"Vallerio","year":"2022","journal-title":"ESMO Open"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.022367","article-title":"Predicting the 10-year risks of atherosclerotic cardiovascular disease in chinese population: the China-PAR project (Prediction for ASCVD risk in China)","volume":"134","author":"Yang","year":"2016","journal-title":"Circulation"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2018.04.059","article-title":"Hepatitis B virus and the risk of coronary heart disease: A comprehensive systematic review and meta-analyses of observational studies","volume":"265","author":"Wang","year":"2018","journal-title":"Int J Cardiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn101460-20231227-00070","article-title":"Potential cardiotoxicity and its mechanism of multi-target tyrosine kinase inhibitors","volume":"8","author":"Han","year":"2024","journal-title":"Chin J Heart Fail and Cardiomyopathy"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-231","article-title":"Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib","volume":"12","author":"Pantaleo","year":"2012","journal-title":"BMC Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12916-023-02838-2","article-title":"Three tyrosine kinase inhibitors cause cardiotoxicity by inducing endoplasmic reticulum stress and inflammation in cardiomyocytes","volume":"21","author":"Wang","year":"2023","journal-title":"BMC Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23042282","article-title":"Mitochondrial toxicity associated with imatinib and sorafenib in isolated rat heart fibers and the cardiomyoblast H9c2 cell line","volume":"23","author":"Bouitbir","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.6515\/acs20150629b","article-title":"Regorafenib-related myocardial injury during atrial fibrillation","volume":"32","author":"Hsiao","year":"2016","journal-title":"Acta Cardiol Sin"},{"key":"B17","doi-asserted-by":"publisher","first-page":"187ra69","DOI":"10.1126\/scitranslmed.3005066","article-title":"Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity","volume":"5","author":"Chintalgattu","year":"2013","journal-title":"Sci Transl Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4236\/ojgas.2020.103005","article-title":"Acute coronary syndrome occurring in a Sub-Saharan patient treated with a reduced dose of sorafenib for an unresectable hepatocellular carcinoma: Case report","volume":"10","author":"Ndam","year":"2020","journal-title":"Open J Gastroenterol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.39779","article-title":"A rare case of regorafenib-induced ST-elevation myocardial infarction","volume":"15","author":"Karki","year":"2023","journal-title":"Cureus"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084232","article-title":"Atherosclerosis and the bidirectional relationship between cancer and cardiovascular disease: from bench to bedside-part 1","volume":"25","author":"Gallucci","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26010334","article-title":"Atherosclerosis and the bidirectional relationship between cancer and cardiovascular disease: from bench to bedside, part 2 management","volume":"26","author":"Gallucci","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11936-020-00866-2","article-title":"Vascular endothelial growth factor (VEGF) inhibitor cardiotoxicity: what should we know","volume":"22","author":"L\u00f3pez-Fern\u00e1ndez","year":"2020","journal-title":"Curr Treat Options Cardio Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: \u2002The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1615472\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T04:14:16Z","timestamp":1756268056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1615472\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":25,"alternative-id":["10.3389\/fonc.2025.1615472"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1615472","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"article-number":"1615472"}}